MassDevice Archives - Page 322 of 587 - Medical Design Sourcing

Steris up on Street-beating Q3 results

Steris (NYSE:STE) reported fiscal third-quarter results that beat the consensus forecast on Wall Street, upping its fiscal 2022 forecast.

The infection prevention technology company — headquartered in Dublin, Ireland and run operationally out of Mentor, Ohio — earned $143.6 million, or $1.42 per share, off $1.2 billion in revenue for the quarter ended Dec. 31, 2021. The results, posted yesterday evening, represented 25% bottom-line growth and 49% top-line growth compared with the previous Q3.

Adjusted to exclude one-time items, earnings per share were $2.12, 16¢ ahead of The Street, where analysts were looking EPS of $1.96 on sales of $1.19 billion.

Get the full story on our sister site Medical Design & Outsourcing.

Insulet appoints Elizabeth Weatherman to board of directors

Insulet (NSDQ:PODD) announced that Elizabeth (Bess) Weatherman was appointed to its board of directors.

Weatherman will stand for election by stockholders at the company’s 2022 annual meeting and has been named to the board’s Compensation Committee.

Get the full story at our sister site, Drug Delivery Business News.

Össur launches next-gen Power Knee

[Image from Össur]Össur (NSDQ:OSSR) announced today that it launched its new Power Knee microprocessor prosthetic knee system.

Stockholm, Sweden-based Össur designed the motor-powered “smart” prosthesis with advanced algorithms for detecting human movement patterns, learning and adjusting to the wearer’s speed and cadence in real-time. The platform creates motion through active powered assistance while distinguishing what type of surface, incline or decline the wearer is on, as well as if they are sitting or standing.

Get the full story at our sister site, Medical Design & Outsourcing.

Amazon launches U.S. telehealth service, plans in-person service rollout in more than 20 cities

Amazon announced that it made its virtual health services available nationwide with plans for a large rollout of in-person services this year.

The company launched Amazon Care in September 2019 to combine virtual care and in-person services, with the latest expansion making the services available nationwide.

According to a news release, Amazon will look to rollout in-person services in more than 20 new cities this year as it invests in the growth of its clinical care team and in-person care services in the country. The company points to the COVID-19 pandemic as a driving factor behind the demand for bringing care to patients’ homes, through both virtual and in-home means.

The company’s in-person services are already available in Seattle, Baltimore, Boston, Dallas, Austin, Los Angeles, Washington, D.C., and Arlington. The planned 2022 expansion includes major metropolitan areas such as San Francisco, Miami, Chicago and New York City.

Ne…

Isoray grows sales 19% in Q2 results

Isoray (NYSE:ISR) posted second-quarter results this week that were in-line with estimates on Wall Street.

The Richland, Washington-based brachytherapy company reported losses of $1.6 million, or -1¢ per share, on sales of $2.82 million for the three months ended Dec. 31, 2021, for a sales growth of 19.4% compared with Q2 2021.

Earnings per share were -1¢, in-line with estimates on The Street, where analysts were looking for sales of $2.8 million.

“This quarter represents the third straight quarter of year over year growth for our core prostate business and other treatment areas including brain, head and neck, and lung cancers. In reviewing this quarter’s results and looking toward the future, we believe the strategies we have been implementing are working and will continue to have a positive impact. We believe Isoray is well-positioned to accelerate our growth as our end markets rebound further from the ongoing effects of the pandemic,” CEO Lori Woods s…

Electromed beats The Street in Q2 results

Electromed (NSDQ:ELMD) posted second-quarter results this week that beat the overall consensus on Wall Street.

The New Prague, Minnesota-based airway clearance maker reported profits of $838,000, or 10¢ per share, on sales of $10.2 million for the three months ended Dec. 31, 2021, for a sales growth of 7.92% compared with Q2 2020.

Earnings per share were 10¢, 3¢ ahead of The Street, where analysts were looking for sales of $9.7 million.

“I’m very pleased to report our second consecutive quarter of record revenue, driven by strong results in our flagship home care segment, with 14.2% growth in-home care revenue in the first six months of our fiscal year compared to the same period in the prior year. Despite difficult macroeconomic conditions and another surge in the COVID-19 pandemic, the team clearly executed at a high level, and we believe these results demonstrate the benefits of our strategic growth initiatives,” CEO Kathleen Skarvan said in a news r…

Inspire Medical Systems beats The Street in Q4, expects strong 2022 sales despite COVID-19 impact

Inspire Medical Systems (NYSE: INSP) shares ticked up today on fourth-quarter results that topped the consensus forecast.

The Minneapolis-based sleep apnea treatment developer posted losses of $2.4 million, or 9¢ per share, on sales of $78.4 million for the three months ended Dec. 31, 2021, for a bottom-line gain closer to breakeven on sales growth of 70.4%.

Inspire Medical’s losses per share of 9¢ came in well ahead of Wall Street projections of 44¢. The company’s revenues also topped analysts’ projections, coming in 0.3% ahead of expectations.

“We experienced significant momentum throughout our business in the fourth quarter,” Inspire Medical Systems President and CEO Tim Herbert said in a news release. “The 70% year-over-year revenue growth achieved in the fourth quarter reflects accelerated patient demand for Inspire therapy and our increasing capacity at new and existing centers. In addition, our ability to improve patient access t…

Teva rises on mixed-bag Q4, sets 2022 guidance

Teva Pharmaceuticals (NYSE:TEVA) shares ticked up this morning on fourth-quarter results that topped the consensus EPS forecast.

The Tel Aviv, Israel-based company posted losses of $159 million, or 14¢ per share, on sales of $4.1 billion for the three months ended Dec. 31, 2021, for a bottom-line slide into the red on a sales decline of 7.9%.

Get the full story at our sister site, Drug Delivery Business News.

Ra Medical closes $12.1M offering

Ra Medical Systems (NYSE:RMED) announced today that it closed its previously announced $12.1 million public offering.

Carlsbad, California-based Ra Medical last week confirmed the pricing of the public offering but did not specify its intended use of proceeds.

The company, which develops an excimer laser system for treating vascular diseases, offered more than 9.5 million units, priced at a public offering price of 50¢ per unit. Each unit consists of one share of common stock, one warrant to purchase one share of common stock at an exercise price of 50¢ per share that expires on the first anniversary of the date of issuance (Series A warrant) and one warrant to purchase one share of common stock at the same price that expires on the seventh anniversary of the date of issuance (Series B warrant).

The company had confirmed when announcing the pricing that it expected the offering to close today, Feb. 8. Ladenburg Thalmann & Co. Inc. acted as the sole …

Medline Industries revenue up nearly 15% in 2021

Medline Industries’ sales grew nearly 15% to $20.1 billion last year as the medtech manufacturer and distributor added more than 230 additional healthcare providers to its prime vendor partnerships.

The new relationships, announced today, were worth nearly $2 billion in annual, incremental sales of medical supplies and services spanning the care continuum. The new health provider partnerships included Northwestern Medicine in Illinois, Rochester Regional Health in New York, Kelsey-Seybold Clinic in Texas, Windsor Lane Health Care in Ohio, Ochsner Health in Louisiana, and Golden LivingCenters in Indiana.

Get the full story on our sister site Medical Design & Outsourcing.

Glaukos announces executive leadership changes

Glaukos this week announced several executive leadership changes that will take place on April 1.

Joseph Gilliam is appointed as president and chief operating officer. He previously served as the chief financial officer and senior VP of corporate development for the San Clemente, California-based company since 2017.

Here are Glaukos’ new executive committee appointments:

Chris Calcaterra will assume the new role of executive VP of global commercial operations. He joined Glaukos in 2008 as chief commercial officer and has served as chief operating officer since February 2017. Alex Thurman will succeed Gilliam to become senior VP and chief financial officer. He joined Glaukos as VP of global tax administration in July 2016 and has served as VP of finance since December 2016. Tomas Navratil will become the company’s new chief development officer. He has served as senior VP of research and development since joining the company in late 2020.

“On…

Johnson & Johnson pauses COVID-19 vaccine production in Dutch plant

The plant will resume production of its COVID-19 vaccine in a matter of months, the paper reported. The company is also working to enlist other facilities to help produce the vaccine, but they are either currently not operational or haven’t received regulatory approval.

While the J&J vaccine has failed to find widespread use in wealthy countries, it remains popular in portions of the developing world, including much of Africa. The vaccine has less-demanding storage requirements than the first generation of mRNA vaccines and offers robust protection against a range of variants when administered as a two-dose series.

Get the full story from our sister site, Pharmaceutical Processing World.